Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors

NCT06128148 is registered in ClinicalTrials.gov with Guangzhou JOYO Pharma Co., Ltd as lead sponsor.

NCT NCT06128148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06128148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors
Lead sponsor
Guangzhou JOYO Pharma Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
May 4, 2022
Completion date
December 30, 2027
Enrollment
101 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, lung neoplasms, other protocol specified criteria, protein kinase inhibitors